Projected Survival Gains from Revising State Laws Requiring Written Opt-in Consent for HIV Testing
- First Online:
- 90 Downloads
Although the Centers for Disease Control and Prevention recommends HIV testing in all settings unless patients refuse (opt-out consent), many state laws require written opt-in consent.
To quantify potential survival gains from passing state laws streamlining HIV testing consent.
We retrieved surveillance data to estimate the current annual HIV diagnosis rate in states with laws requiring written opt-in consent (19.3%). Published data informed the effect of removing that requirement on diagnosis rate (48.5% increase). These parameters then served as input for a model-driven projection of survival based on consent method. Other inputs included undiagnosed HIV prevalence (0.101%); and annual HIV incidence (0.023%).
Hypothetical cohort of adults (>13 years) living in written opt-in states.
Life years gained (LYG).
In the base-case, of the 53,036,383 adult persons living in written opt-in states, 0.66% (350,040) will be infected with HIV. Due to earlier diagnosis, revised consent laws yield 1.5 LYG per HIV-infected person, corresponding to 537,399 LYG among this population. Sensitivity analyses demonstrate that diagnosis rate increases of 24.8-72.3% result in 304,765–724,195 LYG. Net survival gains vanish if the proportion of HIV-infected persons refusing all testing in response to revised laws exceeds 18.2%.
The potential survival gains of increased testing are substantial, suggesting that state laws requiring opt-in HIV testing should be revised.
Key WordsHIV AIDS screening modeling survival analysis
- 2.CDC. HIV/AIDS surveillance report, 2006. Vol 18. Atlanta: Centers for Disease Control and Prevention; 2008. Accessed 5 Jan 2011. Available from http://www.cdc.gov/hiv/topics/surveillance/resources/reports/2006report/pdf/2006SurveillanceReport.pdf.
- 3.District of Columbia DOH. District of Columbia HIV/AIDS epidemiology update, 2008. Washington, DC: District of Columbia Department of Health; 2009. Accessed 5 Jan 2011. Available from http://doh.dc.gov/doh/lib/doh/pdf/dc_hiv-aids_2008_updatereport.pdf.
- 6.CDC. Persons tested for HIV--United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57(31):845-849.Google Scholar
- 11.Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17; quiz CE1-4.Google Scholar
- 15.When To Start Consortium, Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: A collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352-1363Google Scholar
- 21.CDC WONDER On-line Database. Population projections, United States, 2004-2030, by state, age and sex. Atlanta: Centers for Disease Control and Prevention; 2005. Accessed 5 Jan 2011. Available from http://wonder.cdc.gov/population-projections.html.
- 25.DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Rockville: Department of Health and Human Services; 2009. Accessed 5 Jan 2011. Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
- 26.Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV medicine association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1–207. quiz CE1-4.Google Scholar
- 33.Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes–a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43(5):535–540.PubMedGoogle Scholar
- 36.El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community program for clinical research on AIDS and the AIDS clinical trials group. N Engl J Med. 1998;339(26):1889–1895.PubMedCrossRefGoogle Scholar
- 37.Benson CA, Williams PL, Cohn DL, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS clinical trials group 196/Terry Beirn community programs for clinical research on AIDS 009 protocol team. J Infect Dis. 2000;181(4):1289–1297.PubMedCrossRefGoogle Scholar
- 44.CDC. HIV prevalence estimates–United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57(39):1073–1076.Google Scholar